Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;17 Suppl 2(Suppl 2):S38-44.
doi: 10.3747/co.v17i0.698.

Androgen deprivation therapy for prostate cancer-review of indications in 2010

H Quon  1 , D A Loblaw
Affiliations

Androgen deprivation therapy for prostate cancer-review of indications in 2010

H Quon et al. Curr Oncol. 2010 Sep.

Abstract

The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The settings for ADT use include cytoreduction; combined ADT and radiotherapy; pathologic node-positive disease; and recurrent, metastatic, or progressive prostate cancer.

Keywords: Androgen antagonists; combined-modality therapy; disease progression; hormonal anti-neoplastic agents; orchiectomy; prostatectomy; prostatic neoplasms; radiotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Loblaw DA, Pickles T, Cheung PC, Lukka H, Faria S, Klotz L. Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Can Urol Assoc J. 2009;3:460–4. - PMC - PubMed
    1. Klotz L, Boccon–Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase iii study in patients with prostate cancer. BJU Int. 2008;102:1531–8. - PubMed
    1. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74. - PubMed
    1. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (abs) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–99. - PubMed
    1. Whittington R, Broderick GA, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999;44:1107–10. - PubMed

LinkOut - more resources